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Introduction: This study evaluated the addition of gefitinib to
sequential or concurrent chemoradiotherapy (CRT) in unresectable
stage III non-small cell lung cancer.
Methods: Between May 2002 and April 2005, 63 patients were
entered before the study closing early. All received two cycles
paclitaxel 200 mg/m2 and carboplatin area under the curve 6 intra-
venous plus gefitinib 250 mg daily. Poor risk stratum 1 (5%
weight loss and/or performance status 2) received radiotherapy 200
cGy for 33 fractions (6600 cGy) and gefitinib 250 mg daily.
Good-risk stratum 2 (performance status: 0–1weight loss and 5%)
received the same RT with gefitinib 250 mg daily and weekly
paclitaxel 50 mg/m2 plus carboplatin AUC 2. Consolidation gefitinib
until progression was started after all toxicities were grade 2.
Results: Acute high-grade infield toxicities were not clearly in-
creased compared with historical CRT data. Poor-risk (N  21)
median progression-free survival was 13.4 months (95% confidence
interval [CI]: 6.4–25.2) and median overall survival 19.0 months
(95% CI: 9.9–28.4). Good-risk (N  39) median progression-free
survival was 9.2 months (95% CI: 6.7–12.2), and median overall
survival was 13 months (95% CI: 8.5–17.2). Thirteen of 45 tumors
analyzed had activating epidermal growth factor receptor (EGFR)
mutations, and 2 of 13 also had T790M mutations. Seven tumors of
45 had KRAS mutations. There was no apparent survival difference
with EGFR-activating mutations versus wild type or KRAS mutation
versus wild type.
Conclusions: Survival of poor-risk patients with wild type or
mutated EGFR receiving sequential CRT with gefitinib was prom-
ising. Survival for good-risk patients receiving concurrent CRT plus
gefitinib was disappointing even for tumors with activating EGFR
mutations.
Key Words: Gefitinib, Non-small cell lung cancer, Chemoradio-
therapy, Epidermal growth factor receptor.
(J Thorac Oncol. 2010;5: 1382–1390)
The addition of chemotherapy to radiation has improvedboth local control and overall survival (OS) in stage III
non-small cell lung cancer (NSCLC).1–4 Randomized trials
demonstrated that concurrent chemoradiotherapy (CRT) is
superior to sequential CRT in good performance status (PS)
patients. It has not been shown that concurrent CRT is
superior to sequential CRT in patients with PS 2 and/or
weight loss. Induction and consolidation strategies failed to
add to CRT alone.5,6
One strategy to improve outcome for stage III NSCLC
is to add targeted agents to CRT.7 Epidermal growth factor
receptor (EGFR) activation and over expression seem to be
important tumor mechanisms in radiation resistance. EGFR
expression is negatively correlated with local control in
cancers treated with radiation. EGFR activity can be initiated
by a single dose of radiation in experimental models.8 Re-
peated daily radiation stimulates increased EGFR expression
in experimental models.9 EGFR inhibition with small mole-
cule or antibody therapy enhances the activity of radiation in
NSCLC cell lines.10
Gefitinib inhibits EGFR by interfering with adenosine
triphosphate binding.11 The main side effects of gefitinib 250
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mg in phase III studies were rash and diarrhea.12 Patients with
previously treated NSCLC had objective responses to mono-
therapy.13 Gefitinib is most active in patients with NSCLC
with nonsmoking or light smoking history, and East Asian
ancestry.14–16 Activating EGFR mutations and high EGFR
gene-copy number are associated with response to small
molecule EGFR inhibitors.17–20 KRAS mutations are associ-
ated with resistance to gefitinib or erlotinib.21–22
Phase I studies combining paclitaxel and carboplatin
with gefitinib showed modest toxicity.23 Phase III trials
showed no benefit to adding gefitinib to chemotherapy in
unselected patients with advanced NSCLC.24,25 Preclinical
data show additive antitumor efficacy for concomitant radi-
ation and gefitinib.10,26
This trial investigated whether adding gefitinib to sequen-
tial or concurrent CRT improved outcome in nonsurgical stage
III NSCLC. Poor-risk patients (Eastern Cooperative Oncology
Group PS 2 and/or5%weight loss) were stratified to induction
paclitaxel and carboplatin followed by radiation with gefitinib
throughout. Good-risk patients (Eastern Cooperative Oncology
Group PS: 0–1 and 5% weight loss) received the same
induction followed by radiation with concurrent weekly pacli-
taxel and carboplatin with gefitinib throughout. Pretreatment,
paraffin-embedded tumor was collected and analyzed for EGFR-
activatingmutations sensitive to gefitinib,EGFRT790M-activating
mutation resistant to gefitinib, and KRAS mutation.
PATIENTS AND METHODS
Eligible patients had histologic documentation of un-
treated stage III NSCLC. Patients with scalene, supraclavic-
ular, or contralateral hilar lymph node involvement, or direct
invasion of the vertebral body or with a pleural effusion were
ineligible. Radiation oncologist confirmation was required
that radiation could be given per protocol. Eligibility criteria
included Common Toxicity Criteria Performance Status of 0
to 2, tumor specimen paraffin block or unstained slides, and
standard initial laboratory tests. Each participant signed an
institutional review board-approved, protocol-specific in-
formed consent in accordance with federal and institutional
guidelines. Registration and data collection were managed by
the CALGB Statistical Center. Data quality was ensured by
careful review by CALGB Statistical Center staff and study
chairperson following CALGB policies. Accrual was slow on
this trial because participation was limited institution, and a
tumor biopsy specimen for biomarker analysis was required.
Treatment Plan
Patients were stratified to “poor risk” stratum 1 (PS 2
and/or5% weight loss in previous 3 months) or “good risk”
stratum 2 (PS 0–1 5% weight loss) treatment arms. Radi-
ation trials for stage III NSCLC showed that PS 2 or weight
loss is associated with poor survival.27
Both strata received induction chemotherapy with ge-
fitinib, radiation with gefitinib, and gefitinib maintenance
until progression.
Induction chemotherapy consisted of two cycles pacli-
taxel 200 mg/m2 intravenous (IV) every 21 days with carbo-
platin AUC 6 IV plus daily gefitinib 250 mg orally days 1 to
21. Gefitinib was removed from induction May 2004 because
phase III trials showed no benefit of adding gefitinib to
chemotherapy in advanced NSCLC. Standard premeditations
were dexamethasone, diphenhydramine, and cimetidine. Car-
boplatin was calculated at 25 plus creatinine clearance times
AUC according to Calvert formula.28 Creatinine clearance
was determined as 140 minus age times weight in kilograms
divided by 72 times serum creatinine (0.85 for women).
After induction, poor-risk stratum 1 patients received
gefitinib 250 mg daily with radiotherapy (RT). RT consisted of
total dose 66 Gy at 5 fractions/week for 7 consecutive weeks at
2 Gy/fraction. Gefitinib maintenance 250 mg daily began when
all radiation toxicities weregrade 2 and continued until disease
progression or unacceptable side effects.
After induction, good-risk stratum 2 patients received
gefitinib 250 mg daily with concurrent CRT. CRT consisted
of RT to 66 Gy as above plus weekly paclitaxel 50 mg/m2 IV
for 7 weeks with carboplatin AUC 2 IV. Maintenance ge-
fitinib was the same as for stratum 1.
Radiation Therapy
RT began day 43 and was given using photon beams with
energy 4 MV. Target volumes were generally defined by
residual volumes after induction chemotherapy, although the
preinduction computed tomography (CT) scan was reviewed to
determine the originally involved lymph node regions. Target
volume consisted of an original and boost volume. Original
volume included the residual primary lesion, grossly involved
nodal sites (i.e., biopsy positive, CT/magnetic resonance imag-
ing scan nodes 1.0 cm, or any size node with a necrotic
center), plus the ipsilateral hilum and mediastinum with 2 cm
margin. If the primary tumor was in the lung periphery, only one
radiation field was used to cover it and the mediastinum. Con-
tralateral hilum and supraclavicular regions were not treated.
Boost volume excluded the spinal cord and included all sites of
gross disease and the ipsilateral hilum and was limited to50%
of ipsilateral lung volume. Both two-dimensional and three-
dimensional treatment planning systems were allowed. Target
dose to the original volume was 44 Gy in 22 fractions of 2
Gy/fraction; target dose to the boost volume was 22 Gy in 11
fractions. No corrections for lung or bone attenuation were
made. The maximum dose allowed to any point in the spinal
cord was 49 Gy. Central review of the radiation therapy for each
case, including review of diagnostic imaging, was performed at
the Quality Assurance Review Center by the radiation oncology
cochair, chest CT radiologist, and Quality Assurance Review
Center staff.
Chemotherapy Dose Modifications
Induction therapy dose modifications were the same as
CALGB 39801.5 There were no delays, omissions, or dose
reductions for gefitinib.
CRT and gefitinib dose modifications were based on
treatment day counts: platelet 100,000/l or granulocytes
1500/l, chemotherapy was held. There were no gefitinib
dosing modifications for cytopenias. Therapy was discontin-
ued if counts did not return to granulocytes 1500 and
platelets 100,000 after treatment delay of 3 weeks.
For neurotoxicity of grade 3, paclitaxel and gefitinib
were held, and carboplatin was continued at 75% dose level.
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If neurotoxicity improved to grade 1, paclitaxel resumed at
75%, carboplatin 100%, and gefitinib 100% of prior doses.
For hepatic dysfunction with aspartate transaminase 2 to 5
times, upper limits of normal paclitaxel dose was 50% of
previous dose and for aspartate transaminase 5 times upper
limits of normal or bilirubin 1.5 mg/dl paclitaxel and
gefitinib were held. For all other grade 3 toxicity except
alopecia, nausea, vomiting, fatigue, and anorexia, carboplatin
and paclitaxel were reduced by 25%.
For esophagitis, mucositis, stomatitis, and dermatitis of
grade 3, during RT, paclitaxel was held and carboplatin was
continued. Paclitaxel was resumed at a 50% dose once tox-
icity had resolved to grade 2. For grade 4 toxicities, all
protocol therapy was held and resumed after resolution of
toxicity to grade 2. For patients with a decline in PS to3 RT
was completed without further chemotherapy.
Grade 3 esophagitis or other in-radiation field toxicity
was not considered a dose limiting toxicity. Gefitinib was
continued without dose reduction until grade 4 toxicity. For
stratum 1 receiving radiation plus gefitinib experiencing
grade 4 toxicity, all protocol treatment was held. When
toxicity resolved to grade 2, RT was resumed, and gefitinib
was discontinued.
For stratum 2 grade 3 in-field toxicity, paclitaxel was held
and treatment continued with gefitinib, carboplatin, and radia-
tion therapy. For stratum 2 experiencing grade 4 in-field toxicity,
all protocol treatment was held. Radiation and carboplatin re-
sumed when toxicity grade 2, whereas paclitaxel resumed at
50% of prior dose, and gefitinib was discontinued.
EGFR and KRAS Mutation Detection
Analysis was successful on 46 of 60 pretreatment tumor
biopsies. EGFR (exons 18–21) and KRAS (exon 2) mutations
were detected using an enzymatic heteroduplex gene scan-
ning method.29 All positive samples were independently con-
firmed. Primers and polymerase chain reaction conditions are
available on request.
Monitoring
The initial 7 to 9 patients of each stratum were moni-
tored for safety with biweekly conference calls. Accrual was
held until initial cohort safety evaluation was complete.
Statistical Considerations
Analysis was performed by CALGB statisticians.
Planned accrual was 72 eligible patients per stratum with
90% power to differentiate 50% versus 65% treatment
success rate with one-sided significance level of 0.01. Suc-
cess rate was the percentage of patients successfully treated
by the experimental regimen, where “success” was defined as
living longer than 13 months and 14.5 months for poor-risk
and good-risk patients, respectively.
Overall and failure-free survival curves were estimated
using the Kaplan-Meier product-limit method. Failure-free sur-
vival was time between registration and disease relapse or death
whichever came first. Survival time was time between registra-
tion and death. Comparisons of survival were performed using
log-rank test. Planned analysis was to compare survival in
stratum 1 to historical control of poor-risk stage III NSCLC and
stratum 2 to good-risk patients treated on CALGB 39801. The
planned analysis was not performed because accrual goals were
not met. Fisher’s exact test was used to compare treatment
groups with respect to overall response rates and toxicity rates.
All reported p values are two sided.
RESULTS
Study activation was May 2002 and closure April 2005
due to results from Southwest Oncology Group (SWOG) S0023
which showed inferior survival for subjects who received adju-
vant gefitinib after CRT.30
Sixty-three patients were accrued, and 60 (21 poor-risk
stratum 1 and 39 good-risk stratum 2) were eligible. One
patient was deemed ineligible due to inappropriate stage (IB).
Two patients received no protocol treatment and were
deemed nonassessable. The results from 60 patients were
analyzed. Patient characteristics are shown in Table 1.
There were no unexpected toxicities seen for induction
chemotherapy and gefitinib. During induction chemotherapy
and gefitinib, one subject in each stratum had grade 5 toxic-
ities from febrile neutropenia and pneumonia categorized as
pneumonitis/infiltrates in Table 2. Gefitinib toxicities were
rash and diarrhea. There were no reported cases of interstitial
lung disease. There was no clear increase for acute high-
grade in-radiation-field toxicities for CRT plus gefitinib. One
patient receiving maintenance gefitinib developed radiation
pneumonitis confined to the radiation field that responded to
steroid therapy.
Response
Twenty poor-risk patients were evaluated for re-
sponse to induction: 25% partial response (PR), 60% stable
disease, 5% progression, and 10% not assessed (Table 3).
Thirty-eight good-risk patients were evaluated for re-
sponse to induction: 3% complete response (CR), 42%
partial response, 50% stable disease, and 5% progression.
There was a trend toward a higher response rate for the
good-risk stratum 2 patients compared with poor-risk stra-
tum 1 (p  0.16).
The overall best response to induction followed by
radiation plus gefitinib treatment for poor risk was 5% com-
plete response, 48% partial response, 38% stable disease, 5%
progression, and 5% not assessed. Overall best response to
induction followed by concurrent CRT plus gefitinib for good
risk was 5% complete response, 76% partial response, 13%
stable disease, and 5% progression. There was a higher
overall response rate for the good-risk patients compared with
poor risk (p  0.034).
Survival
Poor-risk patients receiving sequential CRT plus gefitinib
had a median progression-free survival (PFS) of 13.4 months
and an overall survival (OS) of 19.0 months (Table 3, Figure 1)
with 62% of patients alive at 13 months. Good-risk patients
receiving induction chemotherapy followed by concurrent CRT
plus gefitinib had disappointing PFS of only 9.2 months and OS
of 13.0 months (Table 3, Figure 2). Mortality from late pulmo-
nary toxicity was well balanced between the strata with 1
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poor-risk patient death from pneumonia/pneumonitis on main-
tenance gefitinib and 2 good-risk patient deaths from pneumo-
nia/pneumonitis off protocol therapy during follow-up.
EGFR Mutations
Forty-five specimens were adequate for EGFR and
KRAS mutation analysis. A total of 13 (29%) tumors had
EGFR-activating mutations. Two of the tumors with L858R
mutations also had T790M mutations that are known to
confer resistance to gefitinib. Tumors with an EGFR gefitinib
sensitive mutation without a T790M resistance mutation were
balanced between the two strata with five in poor-risk stratum
1 and six in good-risk stratum 2. In stratum 1, there were four
tumors with exon 21 L858R mutations and one with a
deletion in exon 19, whereas in stratum 2, there was one
tumor with exon 21 L858R mutation and five tumors with a
deletion in exon 19. Median OS was 5.7 months for exon 19
deletions and 28.4 months for exon 21 L858R mutations; a
formal comparison was not performed because of small
sample size. One poor-risk patient with a T790M mutation
had a best response of SD, PFS 18 months, and OS 21
months. The second patient with a T790M mutation was good
risk and had best response of unconfirmed CR, PFS 8.3
months, and OS 11 months. Patients with T790M mutations
were excluded from the survival analysis of EGFR-activating
mutations. Smoking history and EGFR mutation status were
known for 40 patients. Among the four patients who were
nonsmokers or had less than 10 pack-year smoking history,
one had an activating EGFR mutation. There were 36 heavy
and/or current smokers, and nine (25%) had activating mu-
tations. The two patients with both T790M and L858R
mutations were heavy smokers. There was no difference in
median survival between patients with EGFR mutant tumors
and wild-type tumors (Table 4).
Ras Mutations
Forty-five specimens were adequate for KRAS mutation
analysis. Seven (16%) tumors had KRAS mutations, and there
was no overlap with tumors having EGFR-activating muta-
tions. The presence of a KRASmutation did not seem to affect
outcome, but the sample size is small, and a conclusion
regarding the effect of KRAS cannot be made (Table 4). Of
those tumors with adequate tissue available, there were 3 of
15 (20%) KRAS-positive tumors in stratum 1 and 4 of 30
(13%) KRAS-positive tumors in stratum 2.
DISCUSSION
This is one of the first trials studying CRT with addition
of a concurrent small molecule antagonist of EGFR in unre-
sectable stage III NSCLC. Concurrent gefitinib and RT, and
concurrent gefitinib and CRT had side effects similar to what
would be expected for the same radiation-based therapy
without gefitinib, excepting rashes and diarrhea. There was
no apparent increase in grade 3 or 4 esophagitis from adding
gefitinib to radiation therapy. There were no apparent cases of
interstitial lung disease. One patient in poor-risk stratum 1
developed postradiation pneumonitis in the radiation field
that responded to steroid therapy, and gefitinib may have
been a contributing factor. An Australian phase I trial eval-
uated a similar regimen with gefitinib 250 mg daily, radiation
60 Gy, weekly carboplatin AUC 1.5, and weekly paclitaxel
and reported no apparent increased toxicity of adding ge-
fitinib to CRT.31 Concurrent erlotinib could be given safely at
full dose with two different standard CRT regimens.32
This trial was stopped before full accrual because
results from an unplanned interim analysis of the SWOG trial
in stage III NSCLC that randomized patients to gefitinib or
placebo maintenance therapy after CRT found inferior sur-
vival for patients receiving gefitinib.30 Because sample sizes
were less than planned both in this and the SWOG study, the
TABLE 1. Patient Baseline Characteristics
Poor Risk
Stratum 1
(N  21)
Good Risk
Stratum 2
(N  39)
Overall
(N  60)
Age (yr)
60 5 (24%) 11 (28%) 16 (27%)
60–69 9 (43%) 20 (51%) 29 (48%)
70 7 (33%) 8 (21%) 15 (25%)
Median(min, max) 68 (41, 82) 64 (47, 86) 66 (41, 86)
Gender
Male 16 (76%) 28 (72%) 44 (73%)
Female 5 (24%) 11 (28%) 16 (27%)
Race
White 19 (90%) 36 (92%) 55 (92%)
Black 2 (10%) 1 (3%) 3 (5%)
Unknown 0 (0%) 2 (5%) 2 (3%)
Histological type
Adeno 7 (32%) 13 (33%) 20 (33%)
Squamous 10 (48%) 16 (41%) 26 (43%)
Large cell 2 (10%) 2 (5%) 4 (7%)
NSCLC, NOS 2 (10%) 8 (21%) 10 (17%)
ECOG Performance
Status
0 0 (0%) 18 (46%) 18 (30%)
1 13 (62%) 21 (54%) 34 (57%)
2 8 (38%) 0 (0%) 8 (13%)
Stage
Stage IIIA 9 (43%) 21 (54%) 30 (50%)
Stage IIIB 12 (57%) 18 (46%) 30 (50%)
Smokinga
Non/light distant
smoke
0 (0%) 6 (16%) 6 (11%)
Current/heavy smoke 19 (100%) 32 (84%) 51 (89%)
Smoking years
median (min, max) 40 (15, 55) 35 (5, 50) 38.5 (5, 55)
Pack years of smoking
Median (min, max) 50 (15, 126) 40 (19, 135) 40 (15, 135)
Years of quitting
smoke
Median (min, max) 11.7 (0.02, 30.3) 4.8 (0.02, 40.1) 6.0 (0.02, 40.1)
a The definition of “non/light distant smoke” is a patient who does not have a
history of smoking, or a patient who had no more than 10 pack years and had quit
smoking at least 15 yr ago. The definition of “current/heavy smoke” is a patient who is
currently an active smoker, or a patient who had more than 10 pack years during
smoking history, or a patient who had quit smoking less than 15 yr.
NSCLC, NOS, non-small cell lung cancer not otherwise specified; ECOG, Eastern
Cooperative Oncology Group.
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results from this trial are only appropriate for generating
hypotheses. Data are not available for poststudy therapy.
In this trial, sequential chemotherapy followed by ra-
diation plus gefitinib was studied in poor-risk patients with
PS 2 and/or weight loss. Other studies for “poor risk” stage
III NSCLC reported median OS of approximately 12
months.33,34 The PFS of 13 months and OS of 19 months for
the poor-risk patients on poor-risk stratum 1 receiving se-
quential CRT with gefitinib are promising. CALGB has
planned a follow-up phase II trial in poor-risk patients to test
the hypothesis that small molecule inhibition of EGFR with
radiation alone is beneficial in stage III NSCLC.
The outcome for the good-risk patients in stratum 2
who received induction chemotherapy followed by CRT plus
gefitinib was disappointing with OS of only 13 months.
Therefore, there is no evidence of benefit for adding gefitinib
to concurrent CRT in good-risk patients. Similar disappoint-
ing outcome was reported for a phase I trial combining
erlotinib with CRT in stage III NSCLC.32 SWOG S0023 was
a randomized phase III trial in which gefitinib was given as
maintenance therapy after concurrent CRT and maintenance
docetaxel.30 Survival on the maintenance gefitinib arm was
inferior to the placebo arm. The results for good-risk patients
on our trial receiving gefitinib as part of a concurrent CRT
regimen are consistent with the inferior survival seen when
gefitinib was given as maintenance therapy after concurrent
CRT for stage III NSCLC in SWOG S0023. The mechanism
for inferior survival when gefitinib is given after or during
CRT in stage III NSCLC is not known, whereas there is no
apparent antagonism between cetuximab and CRT in this
setting.35 One could hypothesize that the inhibition of multi-
ple molecular pathways by the multitargeted small molecule
TABLE 2. Summary of Grade 3 Treatment-Related Toxicity by Stratum
Toxicity Stratum
Grade of Adverse Event
Total
3-Severe 4-LifeThr 5-Lethal
n Percentage n Percentage n Percentage
Hemoglobin 1 2 10 0 0 0 0 21
2 1 3 0 0 0 0 40
Neutrophils/granulocytes 1 2 10 7 33 0 0 21
2 9 23 6 15 0 0 40
Platelets 1 0 0 0 0 0 0 21
2 0 0 1 3 0 0 40
Fatigue 1 4 19 1 5 0 0 21
2 12 30 1 3 0 0 40
Radiation dermatitis 1 1 5 0 0 0 0 21
2 1 3 0 0 0 0 40
Anorexia 1 3 14 0 0 0 0 21
2 2 5 0 0 0 0 40
Dehydration 1 2 10 0 0 0 0 21
2 1 3 0 0 0 0 40
Diarrhea 1 2 10 0 0 0 0 21
2 7 18 0 0 0 0 40
Esophagitis 1 4 19 0 0 0 0 21
2 11 28 1 3 0 0 40
Nausea and vomiting 1 0 0 0 0 0 0 21
2 3 8 0 0 0 0 40
Febrile neutropenia 1 0 0 0 0 0 0 21
2 3 8 0 0 0 0 40
Infection without neutropenia 1 2 10 0 0 0 0 21
2 2 5 1 3 0 0 40
Electrolyte 1 2 10 0 0 0 0 21
2 5 13 1 3 0 0 40
Dyspnea/hypoxia 1 6 29 0 0 0 0 21
2 8 20 4 10 0 0 40
Pneumonitis/pulmonary
infiltrates
1 1 5 1 5 1 5 21
2 3 8 1 3 2 5 40
Summary
Maximum overall adverse events 1 7 33 8 38 1 5 21
2 25 63 9 23 2 5 40
A patient who was deemed nonassessable for efficacy analysis due to ineligible disease stage was included in treatment-related
toxicity data.
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gefitinib is antagonistic with CRT, whereas there is no ap-
parent antagonism with specific inhibition of EGFR alone
with cetuximab.
Thirteen of 45 (29%) tumors had EGFR mutations
(exon 19 deletions or L858R) associated sensitivity to ge-
fitinib. One of four nonsmoker or light smoker patients had an
activating mutation. The 25% (9/36) rate of activating EGFR
mutations among heavy and/or current smokers is higher than
would be expected.14–16
The mechanism of acquired resistance to gefitinib is
often the development of a T790M EGFR-activating muta-
tion.35–37 It is surprising that two of the untreated tumors in
this trial presented with both L858R and T790M mutations.
This may be a result of the technique used to detect EGFR
mutations, which is more sensitive than conventional DNA
sequencing.29 Another recent study has also identified EGFR
T790M from EGFR tyrosine kinase inhibitor naive NSCLC
tumor specimens using a sensitive polymerase chain reaction-
based genotyping method.38
NSCLC cell lines with activating EGFRmutations have
a 500 to 1000-fold increased sensitivity to ionizing radiation
even if a T790M mutation is present.39 However, there was
FIGURE 1. Overall survival
and progression-free survival
for poor-risk stratum 1.
TABLE 3. Best Response to Therapy
Induction Treatment Full Treatment
Poor Risk
Stratum 1,
N  20a
Good Risk
Stratum 2,
N  38b
Poor Risk
Stratum 1,
N  21
Good Risk
Stratum,
N  38b
Best response, N (%)
Complete response 0 (0.0) 1 (2.6) 1 (4.8) 2 (5.3)
Partial response 5 (25.0) 16 (42.1) 10 (47.6) 29 (76.3)
Stable 12 (60.0) 19 (50.0) 8 (38.0) 5 (13.1)
Progression 1 (5.0) 2 (5.3) 1 (4.8) 2 (5.3)
Inadequately assessed 2 (10.0) 0 (0.0) 1 (4.8) 0 (0.0)
Response rate, CR  PR%
(95% CI)
25.0% (8.7–49.1) 44.7% (28.6–61.7) 52.4% (29.8–74.3) 81.6% (65.7–92.3)
Two-sided p value from
Fisher’s exact test on
response rate
0.1659 0.0336
a One patient’s response data during induction treatment were unavailable, but the response to full treatment was reported.
b One patient’s response data during induction and full treatment were unavailable.
CI, confidence interval.
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TABLE 4. Kaplan-Meier Product-Limits Estimators of Overall Survival (OS) and Progression-
Free Survival (PFS) for Poor Risk Stratum 1 and Good Risk Stratum 2
Stratum
No. of
Patients (n)
No. of
Events (n)
Median Survival
(mo) (95% CI)
1-Yr Survival Rate
(%) (95% CI)
3-Yr Survival Rates
(%) (95% CI)
OS 1 21 18 19.0 (9.9–28.4) 61.9 (38.1–78.8) 17.6 (3.9–39.6)
2 39 33 13.0 (8.5–17.2) 53.8 (37.2–67.9) 19.2 (8.4–33.3)
PFS 1 21 19 13.4 (6.4–25.2) 57.1 (33.8–74.9) 10.9 (1.9–29.0)
2 39 36 9.2 (6.7–12.2) 35.9 (21.4–50.6) 6.2 (1.2–17.4)
CI, confidence interval.
TABLE 5. Kaplan-Meier Product-Limits Estimators of Overall Survival (OS) and Progression-
Free Survival (PFS) by EGFR and KRAS Mutations
No. of
Patients (n)
No. of
Events (n)
Median Survival
(Mo) (95% CI)
1-Yr Survival Rate (%)
(95% CI)
Log-Rank Test
Two-Sided p
OS
EGFR
WT 32 28 15.3 (10.5–21.2) 62.5 (43.5–76.7) 0.8834
Mutant 11 9 8.5 (5.6–54.4) 45.5 (16.7–70.7)
PFS
WT 32 29 11.4 (7.8–13.8) 43.8 (26.5–59.8) 0.8778
Mutant 11 9 6.7 (2.9–36.3) 36.4 (11.2–62.7)
OS
KRAS
WT 38 33 15.0 (8.6–19.0) 57.9 (40.8–71.7) 0.9167
Mutant 7 6 18.8 (10.5–30.8) 57.1 (17.2–83.7)
PFS
WT 38 34 9.6 (6.8–13.8) 42.1 (26.4–57.0) 0.9918
Mutant 7 6 11.9 (6.7–30.3) 42.9 (9.8–73.4)
CI, confidence interval; EGFR, epidermal growth factor receptor; WT, wild type.
FIGURE 2. Overall survival
and progression-free survival
for good-risk stratum 2.
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no PFS or OS benefit for patients with tumors that had
activating EGFR mutations (Table 4). There was also no
apparent worsened outcome for patients with tumors that had
KRAS mutations. Although the numbers are very small, it is
particularly surprising that the patients with KRAS mutant
tumors did better than patients with EGFR mutant tumors
receiving concurrent CRT with gefitinib further suggesting
unexplained antagonism between CRT and gefitinib.
This trial did not identify a biomarker-defined subset of
patients who might benefit from the addition of gefitinib to
CRT for stage III NSCLC. Overall addition of gefitinib to
sequential CRT for poor-risk patients on this trial was more
promising than the disappointing results for good-risk pa-
tients receiving concurrent CRT. This finding was even more
pronounced for the five poor-risk patients with gefitinib-
sensitive activating EGFR mutations with a median survival
of 28.4 months (95% confidence interval: 5.6–54.4 months,
range 6–54 months) and only 7.2 months (95% confidence
interval: 4.7–17.2 months, range 3–28 months) for six good-
risk patients with gefitinib-sensitive activating EGFR muta-
tions (Table 5). These results could mean that there is antag-
onism with concurrent CRT and gefitinib in tumors with an
EGFR-activating mutation or be due to chance and small
sample size. Patients receiving gefitinib monotherapy in stage
IV NSCLC and an activating EGFR mutation typically have
a survival of approximately 20 months.40,41 However, 12 of
13 patients with EGFR-activating mutations on this trial were
former or current heavy smokers, whereas most patients
studied in the above gefitinib monotherapy trials were non-
smokers or light smokers (Table 6).
There was no benefit for adding gefitinib to concurrent
CRT either in patients with EGFR wild-type or EGFR-
activating mutation tumors. However, this trial is underpow-
ered to draw any conclusions, and these results may have
been due to imbalance in histology, second-line therapy,
smoking history, or other factors. Adding EGFR tyrosine
kinase inhibition therapy to multimodality NSCLC therapy
outside of an IRB-approved trial should be discouraged. The
survival of poor-risk PS 2 and/or weight loss patients with
EGFR wild-type or EGFR-activating mutation tumors receiv-
ing sequential CRT with gefitinib was promising, but the
sample size was small. CALGB plans to conduct a phase II
trial of sequential CRT with chemotherapy alone followed by
concurrent erlotinib and radiation for inoperable patients with
stage III NSCLC with PS 2 and/or weight loss.
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